Who is sponsoring NCT05640531?

NCT05640531 is sponsored by Wockhardt.

What condition does NCT05640531 study?

NCT05640531 studies Bioavailability.

What drugs are being tested in NCT05640531?

Interventions: WCK 771 IV Infusion, Placebo IV Infusion.

What is the status of NCT05640531?

NCT05640531 is currently COMPLETED.

Last reviewed 2022-12-07 · How we verify

Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of Intravenous WCK 771

NCT05640531 PHASE1 COMPLETED

The present study is planned to assess the safety and pharmacokinetic profile in normal healthy subjects in US for WCK 771 with doses ranging from 600 mg to 1000 mg BID for 5 days. In the proposed Phase I MAD study, a subject will be administered 600mg, 800mg, and 1000mg WCK 771 BID for 5 days (Ten doses) or an identical placebo as intravenous infusion.

Details

Lead sponsor	Wockhardt
Phase	PHASE1
Status	COMPLETED
Enrolment	36
Start date	Thu Dec 01 2011 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Wed Jun 27 2012 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Bioavailability

Interventions

WCK 771 IV Infusion
Placebo IV Infusion

Countries

United States